A share price of Cytokinetics Inc [CYTK] is currently trading at $65.6, up 4.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 5.53% over the last week, with a monthly amount glided 3.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on December 18, 2025, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $95 for it. On April 24, 2025, Barclays initiated with a Overweight rating and assigned a price target of $55 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $86 on February 07, 2025. Stifel initiated its recommendation with a Buy and recommended $80 as its price target on January 22, 2025. RBC Capital Mkts started tracking with a Outperform rating for this stock on November 08, 2024, and assigned it a price target of $80. In a note dated August 13, 2024, Goldman downgraded an Neutral rating on this stock and revised its target price from $85 to $60.
Cytokinetics Inc experienced fluctuations in its stock price throughout the past year between $29.31 and $69.33. Currently, Wall Street analysts expect the stock to reach $88.73 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $65.6 at the most recent close of the market. An investor can expect a potential return of 35.26% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Trailing Twelve Months sales for Cytokinetics Inc [NASDAQ:CYTK] were 87.21M which represents 318.14% growth. Gross Profit Margin for this corporation currently stands at -1.28% with Operating Profit Margin at -6.57%, Pretax Profit Margin comes in at -8.62%, and Net Profit Margin reading is -8.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is 2.33 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 62.19 points at the first support level, and at 58.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.99, and for the 2nd resistance point, it is at 74.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cytokinetics Inc [NASDAQ:CYTK] is 6.88. Further, the Quick Ratio stands at 6.88, while the Cash Ratio is 1.59. Considering the valuation of this stock, the price to sales ratio is 91.97.
Transactions by insiders
Recent insider trading involved WENDELL WIERENGA, Director, that happened on Dec 22 ’25 when 20000.0 shares were purchased. EVP Research & Development, Malik Fady Ibraham completed a deal on Dec 16 ’25 to sell 2200.0 shares. Meanwhile, EVP, Chief Commercial Officer Callos Andrew sold 1042.0 shares on Dec 08 ’25.
